Header Ads

My Penny Stock Watch-List for 4.12.2019 ---> 💵💵💯 $VTL

When to use a Watch-list: An investor, for example, may be interested in purchasing stocks in a particular sector. But if that sector is generally overvalued, it may offer few stocks that are attractively priced. An investor could create a list of all the stocks in that sector that would track various valuation measures, including ratios such as trailing price-to-earnings, price-to-sales, price-to-book, among others. When a company on the list met a specified valuation criterion, such as a PE ratio less than 15, he or she would then know that this stock was a possible candidate for investment. Many investment-oriented websites allow visitors to create watch-lists online.


Ticker Symbols: $VTL



VTL - Vital Therapies, Inc. is a biotherapeutic company. It is focused on developing a cell-based therapy targeting the treatment of acute liver failure. The Company operates in the United States, Europe, and China. Vital Therapies, Inc. is based in San Diego, California.




Sign up for Morning Brew

How Might the Immunic Combination with Vital Therapies Impact Investors:

NEW YORK, NY / ACCESSWIRE / April 10, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Vital Therapies, Inc. (VTL) is a biotherapeutic company, focused on developing cell-based therapies for the treatment of acute forms of liver failure.
Vital Therapies announced that its stockholders voted to approve the proposals required to complete the business combination with Immunic AG at a special meeting of Vital Therapies stockholders held Friday.
On Friday, April 5, 2019, VTL shares opened at $.26 per share and reached a high of $.70 per share before closing at $.51 on traded volume of 154.5 million shares.
In September 2018, VTL reported top-line data from a phase 3 clinical trial of ELAD, VTL-308, in 151 subjects with severe alcoholic hepatitis. Although there was a numerical improvement in survival in the ELAD-treated group between three months and one year following randomization, the study failed to meet the primary endpoint of a significant improvement in overall survival through at least ninety-one days. The secondary endpoint of the proportion of survivors at study day ninety-one also showed no statistically significant difference between the groups. The company consequently discontinued the ELAD program.
Day Trading Broker

2 comments:

  1. You penny stock watch list has become such a staple in hanging out with my son. He is always really excited to check it out with me and then "help" me with my trading.

    ReplyDelete
  2. Never stop posting about your penny stocks! I love getting to look at them every week even if I'm not currently trading.

    ReplyDelete

Powered by Blogger.